Patents by Inventor Gary A. Silverman
Gary A. Silverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931366Abstract: The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.Type: GrantFiled: April 19, 2019Date of Patent: March 19, 2024Assignee: Washington UniversityInventors: Stephen Pak, David Perlmutter, Gary Silverman
-
Publication number: 20210228591Abstract: The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.Type: ApplicationFiled: April 19, 2019Publication date: July 29, 2021Inventors: Stephen Pak, David Perlmutter, Gary Silverman
-
Patent number: 9844605Abstract: The present invention relates to methods and compositions for high content drug screening in Caenorhabditis elegans which may be used to identify compounds that treat disorders associated with protein aggregation. It is based, at least in part, on the discovery that Caenorhabditis elegans, genetically modified to create a model system for disorders of protein aggregation, could be used, in a high throughput screening system, to identify agents that reduce the amount of aggregated protein.Type: GrantFiled: July 18, 2014Date of Patent: December 19, 2017Assignee: THE UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Patent number: 9820990Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: GrantFiled: August 25, 2016Date of Patent: November 21, 2017Assignee: THE UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20160361319Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: August 25, 2016Publication date: December 15, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Patent number: 9452171Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: GrantFiled: June 2, 2015Date of Patent: September 27, 2016Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20150265626Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: June 2, 2015Publication date: September 24, 2015Applicant: University Of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Patent number: 9072772Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: GrantFiled: May 3, 2012Date of Patent: July 7, 2015Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20140331341Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EdUcationInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Patent number: 8809617Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: GrantFiled: September 14, 2010Date of Patent: August 19, 2014Assignee: The University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Publication number: 20140047569Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: May 3, 2012Publication date: February 13, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20130024953Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: May 3, 2012Publication date: January 24, 2013Applicant: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20110154510Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: ApplicationFiled: September 14, 2010Publication date: June 23, 2011Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Publication number: 20060287949Abstract: Improved methods, systems, and software are provided for facilitating debt collection by utilizing a non-term life insurance policy for making payments due by debtors to creditors. The life insurance policy can be implemented as, or in conjunction with, a sinking fund for maintaining premium payments received from a debtor under the policy. Periodic and/or lump sum payments to the creditor on behalf of the debtor can be made from the sinking fund, allowing the creditor to receive satisfaction of the debt. Various features can be implemented to provide for the entire amount of debt owed by the debtor to the creditor and further provide cash flow to the creditor after an initial period of contribution. In the event of death of the debtor, the creditor can receive full payment for the outstanding debt.Type: ApplicationFiled: June 16, 2005Publication date: December 21, 2006Inventor: Gary Silverman
-
Publication number: 20060189708Abstract: This invention relates to polymers for self-polishing marine antifouling coatings. More particularly, the invention relates to polymer binders, which provide an erosion rate in seawater that is suitable for use in marine antifouling coatings. These polymer binders contain pendant benzylsilylacrylate groups. Additionally it was found that marine antifouling coatings could be formed with lower silyl acrylate levels using the monomers of the invention, and still achieve a suitable erosion rate in seawater.Type: ApplicationFiled: February 24, 2005Publication date: August 24, 2006Inventors: Michael Abrams, Mark Aubart, Gary Silverman
-
Publication number: 20050255081Abstract: The present invention relates to triorgano phosphites, triorgano amines, heteroaromatic nitrogen compounds, and carbodiimides used as stabilizers for hydrolyzable organic binders. The stabilizers help to prevent viscosity thickening of polymeric binders containing carboxylic ester groups. Without stabilization, the binders can rapidly thicken when exposed to moisture air. The stabilized organic binders of the invention are especially useful for formulating marine antifoulant coatings.Type: ApplicationFiled: April 28, 2005Publication date: November 17, 2005Inventors: Kenneth Tseng, Scot Swan, David Mountz, Mark Aubart, Michael Abrams, Gary Silverman
-
Publication number: 20050256235Abstract: The present invention relates to environmentally sensitive organic binders stabilized by maleic anhydride and its derivatives. The unstabilized binders can rapidly hydrolyze and thicken when exposed to the environment, and especially to moisture. Maleic anhydride and its derivatives act to stabilize these binders. The stabilized organic binders of the invention are especially useful for forming marine antifoulant coatings.Type: ApplicationFiled: April 28, 2005Publication date: November 17, 2005Inventors: Kenneth Tseng, Scot Swan, David Mountz, Mark Aubart, Gary Silverman
-
Patent number: 6422942Abstract: A self-contained electronic unit includes a physically manipulable housing such as a mouse, a feedback device, and processing electronics. The housing is constructed to be moved in its entirety during use by a user. The feedback device is incorporated into the housing and is configured to communicate, to the user, movement of a virtual object within a virtual environment. The processing electronics are incorporated into the housing, and are configured to generate the virtual environment, to respond to movement of the housing in its entirety, without regard to relative movement of the housing with respect to any stationary attached hardware, by causing movement of the virtual object within the virtual environment. A trackball is contained within the mouse housing, and the processing electronics are configured to respond to direct physical manipulation of the trackball by a user to cause movement of the virtual object within the virtual environment.Type: GrantFiled: January 11, 2000Date of Patent: July 23, 2002Inventors: Robert W. Jeffway, Jr., Gary Silverman, Howard R. Tarnoff, Lynn Tarnoff